Lymphoma

Articles

In a phase 1 trial, the recommended phase 2 dose of glofitamab resulted in frequent and durable complete responses for patients with follicular lymphoma and transformed diffuse large B-cell lymphoma arising from follicular lymphoma. 

Grade I to IIA, Transformed Follicular Lymphoma Show Positive Antitumor Response to Glofitamab

Data from the phase 2 ZUMA-5 trial supported the approval of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with follicular lymphoma in the third-line setting. 

FDA Approves Axi-cel in Relapsed/Refractory Follicular Lymphoma

The approval of umbralisib was primarily based on data from the marginal zone lymphoma and follicular lymphoma patient cohorts of the phase 2b UNITY-NHL trial.

FDA Approves Umbralisib for Patients with Previously Treated MZL & FL

In June 2020, the FDA approved tazemetostat (Tazverik) for 2 distinct follicular lymphoma indications based on overall response rate and duration of response observed in phase 2 clinical trial cohorts of patients with follicular lymphoma with EZH2 mutations and wild-type EZH2.

John P. Leonard, MD, on the FDA Approval of Tazemetostat for Follicular Lymphoma

Novartis announced that the study met its primary end point of complete response rate in patients with relapsed or refractory follicular lymphoma.

Phase 2 ELARA Trial Meets Primary End Point in R/R Follicular Lymphoma

The FDA approved tazemetostat for adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, as well as for adult patients with relapsed or refractory FL who have no satisfactory alternative treatment options.

FDA Approves Tazemetostat for 2 Follicular Lymphoma Indications

The FDA granted regenerative medicine advanced therapy designation to tisagenlecleucel for an investigational new indication to treat patients with relapsed or refractory follicular lymphoma.

 FDA Grants RMAT Designation to Tisagenlecleucel for Relapsed/Refractory Follicular Lymphoma

The International Lymphoma Radiation Oncology Group laid out a set of emergency recommendations for alternative radiation treatment schemes for treating patients with hematologic malignancies during the COVID-19 pandemic.

ILROG Recommends Alternative Radiation Treatment Schemes in Blood Cancer During COVID-19 Pandemic

Michael L. Grossbard, MD, suggested that chemo-free regimens, including PI3K inhibitors and a more widespread use of allogeneic stem cell transplant, are being explored as treatment options in this space.

Moving toward Nonchemotherapy-Based Approaches in Follicular Lymphoma

The FDA granted fast track designation to ME-401, an investigational selective oral inhibitor of PI3K delta, for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Follicular Lymphoma | Topics